RecruitingNot a traditional drug phaseinterventionalRules rewrite

Not a traditional drug phase: Inulin for Irritable Bowel Syndrome (IBS)

The study will investigate the relationship between fecal bile acids, short-chain fatty acids (SCFAs), and the gut microbiota in irritable bowel syndrome (IBS). The central hypothesis of this study is that specific shifts in the GI microbiome composition correlate with altered colonic SCFAs and BAs and contribute to IBS symptoms.

Official registry: https://clinicaltrials.gov/study/NCT06668922 · University of California, Los Angeles · enrollment listed as 72

What this phase means

This study does not use the classic phase 1–4 drug ladder. It may be a device, a behavior program, a surgery timing study, or an early feasibility test.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

If you join, the listed intervention(s) are Inulin. The registry lists allocation as randomized. The study will investigate the relationship between fecal bile acids, short-chain fatty acids (SCFAs), and the gut microbiota in irritable bowel syndrome (IBS).

They plan to enroll about 72 people at Los Angeles. Taking part typically means study visits and measurements plus check-ins.

Official title (unrewritten)

Fecal Bile Acids, Fecal Short Chain Fatty Acids and the Intestinal Microbiota in Patients With Irritable Bowel Syndrome (IBS) and Control Volunteers: Diet Challenge

Interventions: Inulin

Primary outcome (registry wording): Total fecal bile acids

Who it is for (from inclusion criteria)

Ages 18 Years to 75 Years
Individuals with irritable bowel syndrome (IBS)
Healthy volunteers (healthy controls) with no prior history of gastrointestinal (GI) disease or symptoms
No dietary restrictions other than vegetarian

Who the registry excludes

Inflammatory bowel disease, celiac disease, or certain types of abdominal cancer, as well as those with thyroid or liver issues
Abdominal surgery or abdominal radiation within 6 months of study participation, with an exception for C-section or gallbladder removal
An exception will be permitted for limited use of stable low doses of antidepressants for individuals who have been taking them for a period greater than one month
Rescue medication such as Bisacodyl (dulcolax) to relieve severe constipation and allow for stool collection will be permitted when needed
Use of Ozempic and Ozempic-type medications
Pregnant or breastfeeding women
Antibiotic use within 3 months of study participation

Contact

No central phone on the registry card. Use the official listing to reach a site.

Sites listed on ClinicalTrials.gov

1 listed

University of California, Los Angeles — Los Angeles, California (recruiting)

Related recruiting trials in this snapshot

RecruitingNot a traditional drug phaseLeuven, Vlaams-Brabant

Not a traditional drug phase: Sample collection for IBS

Aim: More insight in pathogenesis of IBS and IBD. Samples are collected in context of an European research project.

NCT02421705 · Official ClinicalTrials.gov record · KU Leuven

RecruitingNot a traditional drug phaseRochester, Minnesota

Mucosal and Microbiota Changes During Acute Campylobacteriosis

Gastrointestinal (GI) infection with Campylobacter causes inflammation in the bowel and can change bacteria in the gut. Certain individuals with Campylobacter infection are also known to develop chronic bowel problems such as Irritable Bowel Syndrome (IBS).

NCT03223077 · Official ClinicalTrials.gov record · Mayo Clinic

RecruitingPhase 2 / Phase 3Ann Arbor, Michigan

Phase 2 / Phase 3: testing Lexapro for Irritable Bowel Syndrome With Constipation

This study will assess the how well it works of two active treatments with TEA and a chemical neuromodulator (escitalopram aka Lexapro) versus a sham comparator or control group on abdominal pain.

NCT05519683 · Official ClinicalTrials.gov record · University of Michigan

FAQ about this NCT record

Is NCT06668922 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT06668922?

Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT06668922?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary